First-to-File Incentives and 180-Day Exclusivity
First-to-File Incentives and 180-Day Exclusivity Understanding First-to-File ANDA Incentives and 180-Day Exclusivity What Is First-to-File Status in Generic Drug Submissions? Under the Hatch-Waxman Act, the U.S. FDA grants a special marketing incentive to the first applicant who files a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification against a patent listed…
Read More “First-to-File Incentives and 180-Day Exclusivity” »